Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis
Open Access
- 1 January 2008
- journal article
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 6 (1), 4
- https://doi.org/10.1186/1478-7547-6-4
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital DiseasesNew England Journal of Medicine, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical LesionsNew England Journal of Medicine, 2007
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- The predicted effect of changes in cervical screening practice in the UK: results from a modelling studyBritish Journal of Cancer, 2004
- Chapter 2: Natural History of Anogenital Human Papillomavirus Infection and NeoplasiaJNCI Monographs, 2003
- Hysterectomy prevalence and adjusted cervical and uterine cancer rates in England and WalesBJOG: An International Journal of Obstetrics and Gynaecology, 2001
- Mathematical Model for the Natural History of Human Papillomavirus Infection and Cervical CarcinogenesisAmerican Journal of Epidemiology, 2000
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999
- An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyleInternational Journal of STD & AIDS, 1998
- Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age‐dependentInternational Journal of Cancer, 1993